Gilead's twice-yearly shot cut HIV infections by 96% in trial
September 12, 2024 at 09:29 AM EDT
The data sets the stage for likely approval of Gilead's Lenacapavir for HIV prevention.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Copyright 2024. BUSINESS INSURANCE HOLDINGS
